Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31436648 | 1.00 | IRAK4 (0.46) | IRAK4HPGDRAB9AP2RX7NR3C1 | |
| SCHEMBL31436626 | 0.87 | IRAK4 (0.53) | IRAK4HPGD | |
| SCHEMBL26598727 | 0.87 | IRAK4 (0.53) | IRAK4HPGD | |
| SCHEMBL31436632 | 0.85 | IRAK4 (0.46) | IRAK4HPGDRAB9ALRRK2 | |
| SCHEMBL26598650 | 0.85 | IRAK4 (0.46) | IRAK4HPGDRAB9ALRRK2 | |
| SCHEMBL31436622 | 0.85 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL26598605 | 0.85 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL26108232 | 0.83 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL26108220 | 0.83 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL30606157 | 0.82 | HPGD (0.58) | IRAK4HPGDRAB9AP2RX7NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-4511366-A1 | KIT INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205226-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205226-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | IRAK4 753/4885HPGD 4173/4885RAB9A 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.